a registry for people with t-cell lymphoma

Conditions: T-cell Lymphoma; NK-Cell Lymphoma; T-cell Prolymphocytic Leukemia; T-cell Large Granular Lymphocytic Leukemia; Chronic Lymphoproliferative Disorder of NK Cells; Aggressive NK-cell Leukemia; Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder); Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood; Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form; Hydroa Vacciniforme-Like Lymphoproliferative Disorder; Adult T-cell Leukemia/Lymphoma; Extranodal NK/T-cell Lymphoma, Nasal Type; Enteropathy-associated T-cell Lymphoma; Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma; Intestinal T-Cell Lymphoma, Not Otherwise Specified; Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract; Hepatosplenic T-cell Lymphoma; Subcutaneous Panniculitis-Like T-Cell Lymphoma; Mycosis Fungoides; Sezary Syndrome; Primary Cutaneous Anaplastic Large Cell Lymphoma; Primary Cutaneous T-cell Lymphoma; Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma; Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Anaplastic Large Cell Lymphoma, ALK-Positive; Anaplastic Large Cell Lymphoma, ALK-negative; Breast Implant-Associated Anaplastic Large Cell Lymphoma

Summary: the purpose of this registry study is to create a database-a collection of information-for better understanding t-cell lymphoma. researchers will use the information from this database to learn more about how to improve outcomes for people with t-cell lymphoma.


Eligibility criteria:
inclusion criteria: * written informed consent * adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy. * pathologically-confirmed mature t- or natural killer (nk)-cell lymphoma meeting one of the following diagnostic criterion (based on who classification and nccn guidelines): * t-cell prolymphocytic leukemia * t-cell large granular lymphocytic leukemia * chronic lymphoproliferative disorder of nk cells * aggressive nk-cell leukemia * systemic epstein-barr virus (ebv)-positive t-cell lymphoma of childhood * chronic active ebv infection of t- and nk-cell type, systemic form * hydroa vacciniforme-like lymphoproliferative disorder * adult t-cell leukemia/lymphoma * extranodal nk/t-cell lymphoma, nasal type * enteropathy-associated t-cell lymphoma * monomorphic epitheliotropic intestinal t-cell lymphoma * intestinal t-cell lymphoma, not otherwise specified (nos) * indolent t-cell lymphoproliferative disorder of the gastrointestinal tract * hepatosplenic t-cell lymphoma * subcutaneous panniculitis-like t-cell lymphoma * mycosis fungoides (limited to those with ≥ stage ib disease and those receiving active therapy) * sézary syndrome * primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy) * primary cutaneous gamma-delta t-cell lymphoma * primary cutaneous cd8+ aggressive epidermotropic cytotoxic t-cell lymphoma * primary cutaneous acral cd8+ t-cell lymphoma (receiving systemic therapy) * peripheral t-cell lymphoma, not otherwise specified * angioimmunoblastic t-cell lymphoma * follicular t-cell lymphoma * nodal peripheral t-cell lymphoma with tfh phenotype * anaplastic large cell lymphoma, alk-positive * anaplastic large cell lymphoma, alk-negative * breast-implant associated anaplastic large cell lymphoma. * note: patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral cd8+ t-cell lymphoma must be receiving systemic therapy. exclusion criteria: * patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral cd8+ t-cell lymphoma not receiving systemic therapy. * inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. note: repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

Keywords: 23-190 t-cell lymphoma memorial sloan kettering cancer center t-cell lymphoma master repository tclmr